New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
Fat LossAdvanced

NAFLD & Metabolic Liver Disease Protocol

NAFLD & Metabolic Liver Disease Protocol framework focused on consistent execution, practical monitoring, and safer progression.

A comprehensive protocol targeting non-alcoholic fatty liver disease and metabolic-associated steatohepatitis (MASH) through GLP-1 receptor agonism, AMPK activation, and mitochondrial support to reduce hepatic fat and inflammation.

Who it's for

People in Adults with confirmed NAFLD programs with clinician oversightUsers running nafld & metabolic liver disease protocol with structured routinesMASH

Use this as an educational framework with clinical oversight. Keep timing consistent, track response daily, and change one variable at a time after trend review. Pair protocol use with sleep, nutrition, and recovery fundamentals.

Free Peptide Guide

NAFLD & Metabolic Liver Disease Protocol Protocol PDF

Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.

Free, no spam. No catch.

Free access. No spam. This form sends the shared peptide guide that is live today.

Protocol at a Glance

Cycle Duration

Minimum 24 weeks; monitor ALT, AST, liver ultrasound at 12-week intervals

Target Audience

Adults with confirmed NAFLD/MASH, elevated liver enzymes, or metabolic syndrome with hepatic steatosis

CompoundDoseFrequency
Semaglutide

GLP-1 agonist; directly reduces hepatic steatosis, inflammation, and fibrosis markers in NASH trials

0.25 mg escalating to 1–2.4 mgOnce weekly SC
Tirzepatide

GLP-1/GIP dual agonist; superior hepatic fat reduction vs semaglutide alone in head-to-head studies

2.5 mg escalating to 5–15 mgOnce weekly SC
AOD-9604

HGH fragment; activates fat-burning without growth effects; reduces visceral adiposity around liver

300–600 mcgDaily SC
AICAR

AMPK activator; inhibits hepatic de novo lipogenesis and promotes fatty acid oxidation

50–100 mgDaily SC or oral
5-Amino-1MQ

NNMT inhibitor; elevates NAD+ in hepatic tissue, reduces lipid accumulation, improves mitochondrial function

250 mgOnce daily oral
NAD+

Restores hepatic NAD+ levels; supports sirtuin-1 activity critical for fatty acid metabolism

500 mg NMN or NROnce daily oral

Free Peptide Guide

NAFLD & Metabolic Liver Disease Protocol Protocol PDF

Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.

Free, no spam. No catch.

Free access. No spam. This form sends the shared peptide guide that is live today.

Daily Schedule

  1. Morning

    Baseline review and first execution window

    Log sleep, energy, and tolerance; complete planned Semaglutide timing if scheduled.

  2. Midday

    Adherence and symptom check

    Review hydration, workload, and side effects before any changes.

  3. Evening

    Recovery closeout and next-day setup

    Record outcomes, maintain schedule consistency, and prepare next-day protocol.

Safety

  • Escalating side effects or new concerning symptoms require prompt clinical review.
  • Avoid abrupt multi-compound changes during unstable periods.
  • Maintain regular follow-up with a licensed clinician throughout the cycle.

Not appropriate for unsupervised use or as a replacement for diagnosis and medical care. Use only within a clinician-guided plan.

Who should avoid

  • Anyone using this protocol without qualified medical supervision
  • People with unstable medical or psychiatric conditions without specialist guidance
  • Pregnant or breastfeeding individuals unless explicitly cleared by a physician
Open reconstitution calculator

Common Mistakes

Changing multiple variables at once

Why it matters: This makes it hard to identify what improved outcomes versus what increased side effects.

How to fix: Keep one-variable changes per review cycle and log response for several days.

Ignoring adherence and recovery fundamentals

Why it matters: Protocol effectiveness drops when sleep, nutrition, and routine consistency are unstable.

How to fix: Protect daily anchors first, then optimize protocol details gradually.

FAQ

How long should NAFLD & Metabolic Liver Disease Protocol run before reassessment?

A common window is Minimum 24 weeks; monitor ALT, AST, liver ultrasound at 12-week intervals, with periodic review of tolerance and objective trends.

Can I increase complexity quickly for faster results?

Usually no. Safer optimization comes from staged changes and clear tracking.

What should I track each day?

Track schedule adherence, symptoms, sleep quality, and any adverse effects in one log.

Key Takeaways

  • Consistency with Semaglutide + Tirzepatide execution matters more than frequent protocol changes.
  • Single-variable adjustments improve safety and decision quality.
  • Objective daily tracking supports better long-term outcomes.

Why This Stack Works

NAFLD/MASH is driven by insulin resistance, lipid accumulation, mitochondrial dysfunction, and hepatic inflammation. Semaglutide and Tirzepatide reduce hepatic fat through GLP-1/GIP receptor agonism, decreasing lipogenesis and promoting hepatocyte insulin sensitivity. AOD-9604 activates lipolysis pathways specifically targeting visceral adipose tissue adjacent to the liver. AICAR activates AMPK to stimulate hepatic fatty acid oxidation and inhibit de novo lipogenesis. 5-Amino-1MQ inhibits NNMT to shift metabolism toward NAD+-driven mitochondrial repair. NAD+ restores hepatic mitochondrial function and sirtuin-mediated lipid metabolism.

Clinical Research

No clinical references were provided for this stack yet.

More Fat Loss Stacks

Medical disclaimer: This protocol is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.

Free Peptide Guide

NAFLD & Metabolic Liver Disease Protocol Protocol PDF

Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.

Free, no spam. No catch.

Free access. No spam. This form sends the shared peptide guide that is live today.